Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-04-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
投资者关系管理制度(2024年4月修订)
Governance Information Classification · 95% confidence The document is titled "投资者关系管理制度" which translates to "Investor Relations Management System." It is a detailed policy document outlining the principles, responsibilities, and procedures for managing investor relations within the company. It includes chapters on general provisions, content of investor relations management, responsibilities of personnel, communication methods, behavior norms, information disclosure, and appendices. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. It is not an announcement or a brief summary but a governance-related internal policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-19 Chinese
关于使用自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company 亿帆医药股份有限公司 regarding the use of its own funds for entrusted financial management (委托理财). It details the investment type, amount, risk analysis, and approval procedures by the board of directors. The document is relatively short (2043 characters) and does not contain any financial statements or substantive financial data. It is an announcement of a financing-related activity (use of funds for investment in financial products) rather than a full financial report or detailed capital update. Given the content focuses on financing activities and investment of idle funds, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-19 Chinese
《董事会议事规则》修正案
Governance Information Classification · 95% confidence The document is titled as a revision to the "Board Meeting Rules" (董事会议事规则) of 亿帆医药股份有限公司. It contains detailed amendments to the company's internal governance rules, including the roles, responsibilities, and qualifications of directors and independent directors, committee structures, meeting procedures, and other governance-related provisions. There is no indication of financial statements, audit opinions, earnings data, or shareholder voting results. The content focuses on governance practices and board management rules, referencing relevant laws and regulations. Therefore, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-19 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and committee meetings, exercise of duties, communication with auditors, and evaluation of company governance and financial reporting for the year 2023. The content focuses on the independent director's report on their duties and oversight activities during the year, rather than the full annual report or financial statements. This type of document is a management or director report on governance and oversight activities, not a full annual report or audit report. It is not a regulatory filing or announcement but a substantive report by an independent director on their annual duties and observations. Therefore, the best fitting category is "Board/Management Information (MANG)" as it relates to board-level reporting and management oversight information.
2024-04-19 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized report titled "亿帆医药股份有限公司 非经营性资金占用及其他关联资金往来情况的专项报告" which translates to a special report on non-operating fund occupation and other related party fund transactions for the year 2023. It includes detailed financial data tables about fund balances, transactions, and interest related to non-operating funds and related party transactions. The report references an audit opinion issued on April 18, 2024, and is prepared in accordance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is 9353 characters long, which is substantial and contains detailed financial data and analysis, not just an announcement or certification. It is a standalone audit-related report focusing on specific financial and regulatory compliance matters, not a full annual report or interim report. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on specific financial matters, including audit references and detailed financial data, but not the full annual report (10-K) or interim report (IR). FY 2023
2024-04-19 Chinese
募集资金管理办法（2024年4月修订）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理办法' which translates to 'Fundraising Capital Management Measures' and details the management, use, supervision, and regulatory compliance related to the company's raised funds. It extensively covers rules and procedures for handling capital raised through securities issuance, including storage, usage, changes in investment projects, supervision, and reporting requirements. There is no indication that this is an annual or quarterly financial report, audit report, or earnings release. It is a detailed internal policy document related to capital management and fundraising compliance. This fits best under the category of Capital/Financing Update (CAP), as it relates to the management and regulatory framework of the company's fundraising activities and capital usage rather than a financial report or announcement of voting results or governance changes.
2024-04-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.